Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 21/2004

01-11-2004 | Review Article

Management of Acute and Chronic Gouty Arthritis

Present State-of-the-Art

Author: Dr Naomi Schlesinger

Published in: Drugs | Issue 21/2004

Login to get access

Abstract

There are three stages in the management of gout: (i) treating the acute attack; (ii) lowering excess stores of uric acid to prevent flares of gouty arthritis and to prevent tissue deposition of urate; and (iii) providing prophylaxis to prevent acute flares. It is important to distinguish between therapy to reduce acute inflammation in acute gout and therapy to manage hyperuricaemia in patients with chronic gouty arthritis.
During the acute gouty attack nonpharmacological treatments such as topical ice and rest of the inflamed joint are useful. NSAIDs are the preferred treatment in acute gout. The most important determinant of therapeutic success is not which NSAID is chosen, but rather how soon NSAID therapy is initiated. Other treatments include oral and intravenous colchicine, intra-articular and systemic corticosteroids, and intramuscular corticotropin.
Optimal treatment of chronic gout requires long-standing reduction in serum uric acid. The urate-lowering drugs used to treat chronic gout are the uricosuric drugs, the uricostatic drugs, which are xanthine oxidase inhibitors, and the uricolytic drugs. Xanthine oxidase inhibitors such as allopurinol, oxipurinol and febuxastat should be used as first-line treatment in patients with renal calculi, renal insufficiency, concomitant diuretic therapy and ciclosporin (cyclosporine) therapy, and urate overproduction. Uricosuric drugs include probenecid, benzbromarone, micronised fenofibrate and losartan. They are the urate-lowering drugs of choice in allopurinol-allergic patients and underexcretors with normal renal function and no history of urolithiasis. The use of recombinant urate oxidase in patients with chronic gout is limited by the need for parenteral administration, the potential antigenicity and production of anti-urate oxidase antibodies, and declining efficacy.
The effectiveness of colchicine prophylaxis as an isolated therapy is still to be confirmed by placebo-controlled trials. Another issue is prophylaxis with NSAIDs. There are no comparative studies with colchicine.
Footnotes
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literature
1.
Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 1987; 82: 421–6PubMedCrossRef
2.
Yu TF, Gutman AB. Uric acid nephrolithiasis in gout: predisposing factors. Ann Intern Med 1967; 67: 1133–48PubMed
3.
4.
5.
Weede RP. Poison in the pot: the legacy of lead. Carbondale (IL): Southern Illinois University Press, 1984: 83
6.
Comrie JD, editor. Selected works of Thomas Syndenham MD with a short biography and explanatory notes. London: Bale J, Sons and Danielson, 1922
7.
Bacethge BA, Work J, Landreneau MD, et al. Tophaceous gout in patients with renal transplantation treated with cyclosporine A. J Rheumatol 1993; 20: 718–200
8.
Wernick R, Winkler C, Campbell S. Tophi as the initial manifestation of gout: report of six cases and review of the literature. Arch Intern Med 1992; 152: 873–6PubMedCrossRef
9.
Roubenoff R, Klag MJ, Mead LA, et al. Incidence and risk factors for gout in white men. JAMA 1991; 266: 3004–7PubMedCrossRef
10.
Lawrence RC, Hochberg MC, Kelsey JL, et al. Estimates of the prevalence of selected arthritis and Musculoskeletal disease in the United States. J Rheumatol 1989; 16: 427–41PubMed
11.
Mikkelson WH, Dodge HJ, Valkenberg H. The distribution of plasma uric acid values in a population unselected as to gout and hyperuricemia. Am J Med 1965; 39: 242–51CrossRef
12.
O’Sullivan JB. Gout in a New England town: a prevalence study in Sudbury Massachusetts. Ann Rheum Dis 1972; 31: 166–9PubMedCrossRef
13.
14.
Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol 2000; 11: 974–9PubMed
15.
16.
Klemp P, Shelley A, Stansfield SA, et al. Gout is on the increase in New Zealand. Ann Rheum Dis 1997; 56: 22–6PubMedCrossRef
17.
Healy LA, Skeith MD, Decker JL, et al. Hyperuricemia in Filipinos: interaction of heredity and environment. Am J Hum Genet 1967; 19: 81–5
18.
Schlesinger N, Baker DG, Beutler AM, et al. Acute gouty arthritis is seasonal. J Rheumatol 1998; 25: 342–4PubMed
19.
Boss GR, Seegmiller JE. Hyperuricemia and gout: classification, complications and management. N Engl J Med 1979 Jun 28; 300(26): 1459–68PubMedCrossRef
20.
Hall AP, Berry PE, Dawber TR, et al. Epidemiology of gout and hyperuricemia: a long-term population study. Am J Med 1967; 42: 27–37PubMedCrossRef
21.
Perez-Ruiz F, Calabozo M, Erauskin GG, et al. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 2002; 47(6): 610–3PubMedCrossRef
22.
McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med 1961; 54: 452–60PubMed
23.
Lally EV, Zimmerman B, Ho G, et al. Urate mediated inflammation in nodal arthritis: clinical and roentgenographic correlations. Arthritis Rheum 1989; 32: 86–90PubMedCrossRef
24.
Reginato AJ, Schumacher Jr HR. Crystal associated arthropathies. Clin Geriatr Med 1988; 4: 295–322PubMed
25.
Weinberger A, Schumacher HR, Agudelo CA. Urate crystals in asymptomatic metatarsophalangeal joints. Ann Intern Med 1979; 92: 56–7
26.
Bomalaski JS, Lluberas G, Schumacher Jr HR. Monosodium urate crystals in the knee joints of patients with asymptomatic nontophaceous gout. Arthritis Rheum 1986; 29: 1480–4PubMedCrossRef
27.
Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895–900PubMedCrossRef
28.
Schlesinger N, Baker DG, Schumacher Jr HR. Gout: how well have diagnostic tests and therapies been evaluated? Curr Opin Orthop 2000; 11: 71–6CrossRef
29.
Schlesinger N, Baker DG, Schumacher Jr HR. Gout: can management be improved? Curr Opin Rheumatol 2001; 13(3): 240–4PubMedCrossRef
30.
Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kimmen. J Rheumatol 2000; 27: 1045–50PubMed
31.
Lin KC, Lin HY, Chou P. The interaction between SUA level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 2000; 27: 1501–5PubMed
32.
Nicholas A, Scott JT. Effect of weight loss on plasma and urinary levels of uric acid. Lancet 1972; II: 1223–4
33.
Fam AG. Gout, diet, and the insulin resistance syndrome. J Rheumatol 2002; 29: 1350–5PubMed
34.
Dessein PH, Shipton AE, Stanwix AE, et al. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 2000; 59: 539–43PubMedCrossRef
35.
Sharpe CR. A case controlled, study of alcohol consumption and drinking behaviour in patients with acute gout. CMAJ 1984; 131: 563–7
36.
Agudelo CA, Schumacher Jr HR, Phelps P. Effect of exercise on urate crystal-induced inflammation in canine joints. Arthritis Rheum 1972; 15: 609–16PubMedCrossRef
37.
Schumacher Jr HR. Crystal induced arthritis: an overview. Am J Med 1996; 100 Suppl. 2A: 46–52CrossRef
38.
Schlesinger N, Baker DG, Beutler AM, et al. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 2002; 29: 331–4PubMed
39.
Dorwart BB, Hansell JR, Schumacher Jr HR. Effects of cold and heat on urate-induced synovitis in dog. Arthritis Rheum 1974; 17: 563–71PubMedCrossRef
40.
Pittman JR, Bross MH. Prognosis and management of gout. Am Fam Physician 1999; 59: 1799–806PubMed
41.
Carew M, Roberts K. Care of the patient with gout. Geriatr Nurs 2000; 20: 156–7
42.
Porter R, Rousseau GS, editors. Gout: the patrician malady. New Haven (CT): Yale University Press, 1998
43.
Singer C. A history of scientific ideas. New York: Barnes and Noble Books, 1996
44.
Peletier PS, Caventon J. [Title unknown]. Ann Chim Phys 1820; 14: 69
45.
Corrodi H, Hardegger E. Die Konfiguration des Colchicins und verwandter Verbindungen. Helv Chem Acta 1955; 38: 2030–3CrossRef
46.
Katzung BG, editor. Basic and clinical pharmacology. 6th ed. Norwalk (CT): Appleton and Lange, 1995: 536–59
47.
Levy M, Spino M, Read SE. Colchicine: a state-of-the-art review. Pharmacotherapy 1991; 11: 196–211PubMed
48.
Ahern MJ, Reid C, Gordon TP. Does colchicine work? Results of the first controlled study in gout. Aust N Z J Med 1987; 17: 301–4PubMedCrossRef
49.
Paulus HE, Schlosstein LH, Godfrey RC, et al. Prophylactic colchicine therapy in intercritical gout. Arthritis Rheum 1974; 17: 609–14PubMedCrossRef
50.
51.
52.
Wallace SL, Singer JZ. Review: systemic toxicity associated with the intravenous administration of colchicine: guidelines for use. J Rheumatol 1988; 15: 495–9PubMed
53.
Guazzo E. Use of intravenous colchicine for podagra [letter]. Am Fam Physician 1999; 60: 2504–5PubMed
54.
Stephan WH. Use of intravenous colchicine in patients with acute gout [letter]. Am Fam Physician 2000; 61: 2343–4PubMed
55.
Evans IT, Wheeler MT, Small RE, et al. A comprehensive investigation of inpatient colchicine use shows more education is needed. J Rheumatol 1996; 23: 143–8PubMed
56.
Allison MC, Howatson AG, Torrance CJ, et al. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med 1992; 327: 749–54PubMedCrossRef
57.
Sandier DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991; 115: 165–72
58.
Kelly W, Wortmann RL. Crystal-associated synovitis: gout and hyperuricemia. In: Kelly W, editor. Textbook of rheumatology. 4th ed. Philadelphia (PA): Saunders, 1993: 1340–51
59.
Smyth CJ, Percy JS. Comparison of indomethacin and phenylbutazone in acute gout. Ann Rheum Dis 1973; 32(4): 351–3PubMedCrossRef
60.
Ruosti A, Vainio U. Treatment of acute gouty arthritis with proquazone and indomethacin: a comparative double-blind trial. Scand J Rheumatol Suppl 1978; 21: 15–7
61.
Altaian RD, Honig S, Levin JM, et al. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J Rheumatol 1988; 15: 1422–6
62.
Weiner GI, White SR, Weitzner RI, et al. Double blind study of phenoprofen versus phenylbutazone in acute gouty arthritis. Arthritis Rheum 1979; 22: 425–6PubMedCrossRef
63.
Shrestha M, Morgan DL, Moreden JM, et al. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med 1995; 26: 682–6PubMedCrossRef
64.
Maccagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac (Lodine) compared with naproxen in patients with acute gout. Curr Med Res Opin 1991; 12: 423–9PubMedCrossRef
65.
Schumacher HR, Boice J, Dahikh DI, et al. Randomized double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ 2002; 324: 1488–92PubMedCrossRef
66.
Gordon GV, Schumacher Jr HR. Management of gout. Am Fam Physician 1969; 10: 62–6
67.
Gray RG, Tenenbaum J, Gottlieb NL. Local corticosteroid injection treatment in rheumatic disorders. Semin Arthritis Rheum 1979; 10: 231–54CrossRef
68.
Fernandez C, Noguera R, Gonzalez JA, et al. Treatment of acute attacks of gout with small doses of intraarticular triamcinolone acetonide. J Rheumatol 1999; 26: 2285–6PubMed
69.
Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 1990; 19: 329–36PubMedCrossRef
70.
Alloway JA, Moriarty MJ, Hoogland YT, et al. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1993; 20: 111–3PubMed
71.
Getting SJ, Christian HC, Flower RJ, et al. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum 2002 Oct; 46(10): 2765–75PubMedCrossRef
72.
Ritter J, Kerr LD, Valeriano-Marcet J, et al. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol 1994; 21: 696–9PubMed
73.
Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988; 31: 803–5PubMedCrossRef
74.
Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of gouty arthritis. J Rheumatol 1994; 21: 1325–7PubMed
75.
Li-Yu J, Clayburne G, Sieck M, et al. Treatment of chronic gout: can we determine when stores are depleted enough to prevent attacks of gout? J Rheumatol 2001; 28: 577–80PubMed
76.
Gutman AB. Gout. In: Beeson PB, McDermott W, editors. Textbook of medicine. 12th ed. Philadelphia (PA): WB Saunders, 1958: 895
77.
Fam AG. Should patients with interval gout be treated with urate lowering drugs? J Rheumatol 1995; 22: 1621–3PubMed
78.
Emmerson BT. The management of gout. N Engl J Med 1996; 334: 455–551
79.
Ferraz MB. An evidence based appraisal of the management of tophaceous interval gout. J Rheumatol 1995; 22: 1618–20PubMed
80.
Perez-Ruiz F, Alonso-Ruiz A, Calaabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricemia: a pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998; 57(9): 545–9PubMedCrossRef
81.
Hepburn AL, Kaye SA, Feber MD. Fenofibrate is a new treatment of hyperuricemia and gout? Ann Rheum Dis 2001; 60: 984–6PubMedCrossRef
82.
Shahinfar S, Simpson RL, Carides AD, et al. Safety of losartan in hypertensive patients with hyperuricemia. Kidney Int 1999; 56: 1879–85PubMedCrossRef
83.
Schumacher Jr HR, Moreno-Alvarez JM. Clued to common crystal induced arthropathies. Intern Med 1993; 14: 35–47
84.
Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum 1986; 29: 82–7PubMedCrossRef
85.
Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76(1): 47–56PubMedCrossRef
86.
Levinson DJ, Becker MA. Clinical gout and the pathogenesis of hyperuricemia. In: McCarty DJ, Koopman WJ, editors. Arthritis and allied conditions. 12th ed. Philadelphia (PA): Lea and Febriger 1993: 1773–818
87.
Bull PW, Scott JT. Intermittent control of hyperuricemia in the treatment of gout. J Rheumatol 1989; 16: 1246–8PubMed
88.
Osada Y, Tsuchimoto M, Fukushima H, et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, febuxostat, in rodents. Eur J Pharmacol 1993; 241: 183–8PubMedCrossRef
89.
Komoriya K, Osada Y, Hasegawa M, et al. Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor febuxostat in chimpanzees. Eur J Pharmacol 1993; 250: 455–60PubMedCrossRef
90.
Swan S, Khosraven R, Mayer M, et al. Effect of renal impairment on pharmacokinetics, pharmacodynamics and safety of febuxostat (TMX-67), a novel non-purine selective inhibitor of xanthine oxidase [abstract]. Arthritis Rheum 2003; 48 Suppl. 9:529
91.
Joseph-Ridge N. Phase II, dose-response, safety and efficacy clinical trial of a new oral xanthine oxidase inhibitor TMX-67 (febuxostat) in subjects with gout [abstract]. Arthritis Rheum 2002; 46 Suppl. 9: 289
92.
Bellamy N, Gilbert JR, Brooks PM, et al. A survey of current prescribing practices of anti-inflammatory and urate lowering drugs in gouty arthritis in the Province of Ontario. J Rheumatol 1988; 15: 1841–71PubMed
93.
Medellin MV, Erickson AR, Enzenauer RJ. Variability of treatment for gouty arthritis between rheumatologists and primary care physicians. J Clin Rheumatol 1997; 3: 24–7PubMedCrossRef
94.
Pawlotsky Y. What is the optimal treatment for acute crystal induced arthritis? Rev Rheum Engl Ed 1996; 63: 231–3
95.
Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895–900PubMedCrossRef
96.
Weinberger A, Pinkhas J. The efficacy of treatment with allopurinol versus uricosuric drugs in gout. Panminerva Med 1978 Jul–Sep; 20(3): 155–6PubMed
97.
Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med 1966; 64: 229–58PubMed
98.
Beutler AM, Rull M, Schlesinger N, et al. Treatment with allopurinol decreases the number of acute gout attacks despite persistently elevated serum uric acid [letter]. Clin Exp Rheumatol 2001; 19: 595PubMed
99.
Scott JT. Comparison of allopurinol to probenecid. Ann Rheum Dis 1966; 25: 623–6PubMed
100.
101.
Bomalaski JS, Clark MA. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. Curr Rheumatol Rep 2004 Jun; 6(3): 240–7PubMedCrossRef
102.
Nishimura H, Matsushima A, Inada Y. Improved modification of yeast uricase with polyethylene glycol, accompanied with nonimmunoreactivity towards anti-uricase serum and high enzymic activity. Enzyme 1981; 26: 49–53PubMed
103.
Bomalaski JS, Holtsberg FW, Ensor CM, et al. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol 2002 Sep; 29(9): 1942–9PubMed
104.
105.
106.
Yu TF, Gutman AB. Efficacy of colchicine prophylaxis in gout. Ann Intern Med 1961; 55: 179–92PubMed
107.
Yu TF. The efficacy of colchicine prophylaxis in articular gouta reappraisal after 20 years. Semin Arthritis Rheum 1982; 12: 258–64CrossRef
Metadata
Title
Management of Acute and Chronic Gouty Arthritis
Present State-of-the-Art
Author
Dr Naomi Schlesinger
Publication date
01-11-2004
Publisher
Springer International Publishing
Published in
Drugs / Issue 21/2004
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200464210-00003

Other articles of this Issue 21/2004

Drugs 21/2004 Go to the issue

Review Article

Long-Cycle Treatment with Oral Contraceptives

Review Article

Trospium Chloride in the Management of Overactive Bladder

Review Article

Aspirin-Induced Asthma

Leading Article

Therapeutic Potential of Oral Antiproliferative Agents in the Prevention of Coronary Restenosis

Adis Drug Evaluation

Gefitinib

Therapy in Practice

Topical Antibacterial Therapy for Acne Vulgaris